Product Description
Interferon alfacon-1 (consensus interferon) is a non-naturally occurring, synthetic, type 1 interferon (IFN)alpha that is used for the treatment of patients with chronic hepatitis C. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11577799/)
Mechanisms of Action: IFN Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|